Logo: to the web site of Uppsala University

uu.sePublikasjoner fra Uppsala universitet
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study
Erasmus MC, Dept Pathol, POB 2040, NL-3000 CA Rotterdam, Netherlands..
Erasmus MC, Dept Pathol, POB 2040, NL-3000 CA Rotterdam, Netherlands..
Erasmus MC, Dept Pathol, POB 2040, NL-3000 CA Rotterdam, Netherlands..
Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands..
Vise andre og tillknytning
2017 (engelsk)Inngår i: Journal of Urology, ISSN 0022-5347, E-ISSN 1527-3792, Vol. 197, nr 6, s. 1410-1418Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Purpose: Patients with nonmuscle invasive bladder cancer are followed with frequent cystoscopies. In this study FGFR3, TERT and OTX1 were investigated as a diagnostic urinary marker combination during followup of patients with primary nonmuscle invasive bladder cancer.

Materials and Methods: In this international, multicenter, prospective study 977 patients with nonmuscle invasive bladder cancer were included. A total of 2,496 urine samples were collected prior to cystoscopy during regular visits. Sensitivity was estimated to detect concomitant recurrences. Kaplan-Meier curves were used to estimate the development of future recurrences after urinalysis and a negative cystoscopy.

Results: Sensitivity of the assay combination for recurrence detection was 57% in patients with primary low grade, nonmuscle invasive bladder cancer. However, sensitivity was 83% for recurrences that were pT1 or muscle invasive bladder cancer. Of the cases 2% progressed to muscle invasive bladder cancer. Sensitivity for recurrence detection in patients with primary high grade disease was 72% and 7% of them had progression to muscle invasive bladder cancer. When no concomitant tumor was found by cystoscopy, positive urine samples were more frequently followed by a recurrence over time compared to a negative urine sample (58% vs 36%, p < 0.001). High stage recurrences were identified within 1 year after a positive urine test and a negative cystoscopy.

Conclusions: Recurrences in patients with primary nonmuscle invasive bladder cancer can be detected by a combination of urine assays. This study supports the value of urinalysis as an alternative diagnostic tool in patients presenting with low grade tumors and as a means to identify high stage tumors earlier.

sted, utgiver, år, opplag, sider
2017. Vol. 197, nr 6, s. 1410-1418
Emneord [en]
urinary bladder neoplasms, neoplasm recurrence, local, urinalysis, cystoscopy, neoplasm invasiveness
HSV kategori
Identifikatorer
URN: urn:nbn:se:uu:diva-324238DOI: 10.1016/j.juro.2016.12.096ISI: 000400896400010PubMedID: 28049011OAI: oai:DiVA.org:uu-324238DiVA, id: diva2:1110103
Forskningsfinansiär
EU, FP7, Seventh Framework Programme, 201663Tilgjengelig fra: 2017-06-15 Laget: 2017-06-15 Sist oppdatert: 2017-06-15bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMed

Person

Segersten, UlrikeMalmström, Per-Uno

Søk i DiVA

Av forfatter/redaktør
Segersten, UlrikeMalmström, Per-Uno
Av organisasjonen
I samme tidsskrift
Journal of Urology

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 522 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf